The numbers tell a more nuanced story than the models give credit for. TTM revenue of $1.12B is up just 8.1% year-over-year, but that figure is a lagging artifact of the weak September 2025 quarter ($218.2M, down 13.5% from the prior-year $252.2M). Strip that out and the trajectory is unambiguous: $266.9M in January 2026, $291.9M in March, $343.1M in June — the latest quarter is up 35.3% YoY and 17.5% QoQ, the strongest print in the entire eight-quarter dataset. The "mature_earner" classification at 0.7 confidence is wrong; this is a company in the middle of a growth inflection, not a steady-state equipment maker. The earnings picture is messier. TTM net income of $132.6M is down 33.7% from $199.9M a year ago, driven almost entirely by the January 2026 quarter's 3.9% net margin ($10.5M on $266.9M revenue) — a level that has never appeared in the prior-year data and almost certainly reflects a one-time charge, restructuring cost, or tax item rather than structural margin erosion. The June 2026 quarter's 17.5% margin is a return to the company's historical 13-24% band, and the 30% FCF margin on $299.8M of free cash flow against a zero-debt balance sheet with $346.1M in cash is a genuinely fortress-grade financial profile. The 100x trailing P/E and 60.8x EV/EBITDA look absurd in isolation, but they are computed against a depressed earnings base. If margins normalize to 18-20% on the accelerating revenue run-rate, TTM earnings within two quarters could be $180-200M, compressing the forward multiple to 80-90x — still rich, but no longer the 100x the headline implies.

The Valuation Synthesis's $75-80 fair value is, in my view, too low by a wide margin. A DCF at 12% FCF growth, 3% terminal, 10% discount rate yields roughly $120-130 per share; at 18% growth — which the 35% YoY revenue acceleration and the AI advanced-packaging capex cycle at TSMC, Samsung, and Intel arguably support — it lands closer to $160-180. The synthesis is anchoring on the 8.1% TTM revenue growth and the 11.7% five-year CAGR, both of which are backward-looking and flattered by the 2022 peak ($1.01B revenue, $223M net income) that the company has not yet recovered. The Pre-Flight's observation that the market is pricing in 15-25% sustained revenue CAGR is the right question, and the June quarter's 35% YoY print is the first data point that actually supports that range. The Market Narrative layer correctly identifies that the $268 price is "almost entirely narrative" above the cash-flow floor, but it undersells the durability of that narrative: Onto's metrology and inspection tools are not a nice-to-have in CoWoS and HBM stacking, they are a process-control necessity, and the competitive set (KLA, AMAT) is expanding into advanced packaging but has not yet demonstrated equivalent tooling depth in that specific niche. The "platform-monopoly" archetype with "strong" narrative intensity is defensible, not just a sell-side framing exercise.

Where I part with the models is on the magnitude of the overvaluation and the insider data. The synthesis says the stock is 70% overvalued; I'd put it at 35-45% overvalued, implying a fair-value band of $150-175 rather than $75-80. The 52-week range of $101 to $386 tells you this stock has already been through a violent re-rating and a 30% pullback from its high; $268 is not the euphoric top, it's the middle of a wide range. The insider transaction data is essentially uninformative — all ten entries are A-Award vesting (761 shares each, five entries on May 20) and F-InKind transfers (218-819 shares), which are administrative equity events, not discretionary open-market buys or sells. The "No Insider Transactions" secondary signal is technically accurate but misleadingly clean; it simply means no one is buying or selling in the open market, which is normal for a $16B-cap name where insiders hold through trusts and 10b5-1 plans. The ROIC anomaly (annual 6.4% vs. TTM 16.9%, a 165% gap) is the single most important data point in the file: it tells you the company's capital efficiency is improving rapidly, which is consistent with the revenue acceleration and margin recovery, and it means the TTM multiples are computed against a still-depressed earnings base that will normalize. The one genuine red flag is the "Macro Headwinds" and "Below Sector Benchmarks" secondary signals, which suggest the broader semi-equipment cycle is not uniformly supportive, and the "Macro Headwinds" tag is the kind of thing that could turn a 35% YoY revenue print into a 10% one within two quarters if AI capex digestion hits.

The contrarian case for owning at $268 is not that the DCF supports it — it doesn't, not at any reasonable growth rate below 25% — but that the revenue inflection is real, the balance sheet is bulletproof, the AI packaging TAM expansion is multi-year and multi-fab, and the stock has already de-risked 30% from its high. The case against is that 100x trailing earnings with 8% TTM growth is a valuation that requires the next four quarters to deliver 25%+ revenue growth and 18%+ net margins simultaneously, with zero competitive disruption from KLA or AMAT in advanced-packaging metrology, and with the AI capex cycle not pausing. That is a lot of "and"s. I am not comfortable calling this undervalued, and I am not comfortable calling it 70% overvalued. It is a high-quality company at a price that demands the AI packaging story plays out on schedule, and the June quarter's 35% YoY print is the first quarter that actually justifies the premium.